ADMINISTRATION OF MOST CLOSELY MATCHED THIRD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH EBV-POSITIVE LYMPHOMA AND OTHER EBV-POSITIVE MALIGNANCIES

Description

The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments. This research study uses special immune system cells called LMP, BARF-1 and EBNA1- specific cytotoxic T lymphocytes (MABEL CTLs). Some patients with Lymphoma (such as Hodgkin (HD) or non-Hodgkin Lymphoma (NHL)), T/NK-lymphoproliferative disease, or CAEBV, or solid tumors such as nasopharyngeal carcinoma (NPC), smooth muscle tumors, and leiomyosarcomas show signs of a virus called EBV before or at the time of their diagnosis. EBV causes mononucleosis or glandular fever ("mono" or the "kissing disease"). EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells (in CAEBV) infected by EBV are able to hide from the body's immune system and escape dest

Trial Eligibility

Inclusion Criteria: SCREENING 1. Any patient regardless of age or sex, with diagnosis of either: * EBV positive Hodgkin's lymphoma * EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype) * EBV (associated)-T/NK-lymphoproliferative disease * Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV * Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.) AND * in first or subsequent relapse (Group A) * with active disease persisting despite therapy (Group B) * with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C) 2. EBV positive tumor 3. Weighs at least 12kg 4. Informed consent (and assent as applicable) obtained from patient/guardian. TREATMENT 1. Any patient regardless of age or sex, with diagnosis of either: * EBV positive Hodgkin's lymphoma * EBV Positive non-Hodgkin's Lymphoma (regardless of histologic subtype) * EBV (associated)-T/NK-lymphoproliferative disease * Severe Chronic Active EBV (CAEBV) -- CAEBV is defined as patients with high EBV viral load in plasma or PBMC (\>4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV * Other EBV positive malignancies (e.g. nasopharyngeal carcinoma, smooth muscle tumors, etc.) AND * in first or subsequent relapse (Group A) * with active disease persist despite therapy (Group B) * with active disease if immunosuppressive chemotherapy is contraindicated e.g. patients who develop Hodgkin disease after solid organ transplantation or if the lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group C) 2. EBV positive tumor 3. Patients with life expectancy greater than or equal to 6 weeks 4. Patients with bilirubin less than or equal to 3x upper limit of normal 5. AST less than or equal to 5x upper limit of normal 6. Hemoglobin greater than or equal to 7.0 (may be a transfused value) 7. Patients with a creatinine less than or equal to 2x upper limit of normal for age 8. Pulse oximetry of \> 90% on room air 9. Patients should have been off other investigational therapy for 30 days prior to infusion. 10. Patients with a Karnofsky/Lansky score of more than or equal to 50. 11. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom. 12. Informed consent (and assent as applicable) obtained from patient/guardian. Exclusion Criteria: TREATMENT 1. Pregnant or lactating 2. Severe intercurrent infection 3. Current use of systemic corticosteroids more than 0.5 mg/kg/day 4. Patients receiving ATG, Campath, or other immunosuppressive T cell monoclonal antibodies within 30 days.

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.